Trials / Withdrawn
WithdrawnNCT03785184
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
A Phase 2, Multicenter, Single Arm, Open Label Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and preliminary efficacy of venetoclax when combined with lenalidomide and dexamethasone for participants with newly diagnosed, active t(11;14) positive multiple myeloma (MM). This study will consist of 2 parts: Part 1 Dose Escalation and Part 2 Dose Expansion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | venetoclax | tablet; oral |
| DRUG | lenalidomide | capsule; oral |
| DRUG | dexamethasone | tablet; oral |
Timeline
- Start date
- 2019-04-29
- Primary completion
- 2019-08-22
- Completion
- 2019-08-22
- First posted
- 2018-12-24
- Last updated
- 2019-08-28
Locations
22 sites across 4 countries: United States, Australia, Canada, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03785184. Inclusion in this directory is not an endorsement.